Daily Tech News Show
Android OS development stays open while going private - DTNSB 4985
Mar 27, 2025
Tech journalist Tom Merritt dives into Google's recent shift in Android development, discussing the move to internal branches and its effects on the developer community. He contrasts the open-source principles of Android with Google's growing business influence. The conversation touches on the gaming innovation of Nintendo's Virtual Game Cards, and the evolving landscape of technology, including AI advancements. Merritt also draws intriguing connections between tech and our love for animals, making the discussion both insightful and engaging.
28:40
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- EBCLIS shows promise for long-term eczema relief, with about 40% of users experiencing significant improvement after 16 weeks.
- The podcast highlights the importance of community support among eczema patients in sharing insights and managing their condition effectively.
Deep dives
Efficacy of EBCLIS for Eczema Relief
EBCLIS, also known as LibriKizumab, has shown promise in treating moderate to severe eczema in both adults and children. After an initial dosing period of 16 weeks, approximately 40% of participants reported significant itch relief and achieved clear or nearly clear skin. Furthermore, a considerable number of these patients maintained improved skin conditions for up to a year with monthly injections of the medication. This illustrates EBCLIS's potential as a long-term solution for individuals struggling with eczema not well managed by traditional topical treatments.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
